Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas

[1]  S. Horvath,et al.  Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma , 2009, Stem cells.

[2]  T. Mikkelsen,et al.  Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. , 2008, Neuro-oncology.

[3]  A. Reynolds,et al.  Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis , 2008, Angiogenesis.

[4]  R. Perona,et al.  Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[5]  M. Prados,et al.  Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. , 2008, Neuro-oncology.

[6]  L. Ricci-Vitiani,et al.  Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts , 2008, International journal of cancer.

[7]  A. Shervington,et al.  Chemoresistance in gliomas , 2008, Molecular and Cellular Biochemistry.

[8]  G. Lesser,et al.  Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas , 2008, Current treatment options in oncology.

[9]  B. Halmos,et al.  SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2 , 2008, Anti-cancer drugs.

[10]  M. Nicholas,et al.  Glioblastoma multiforme: evidence-based approach to therapy , 2007, Expert review of anticancer therapy.

[11]  Santosh Kesari,et al.  Molecular pathogenesis of adult brain tumors and the role of stem cells. , 2007, Neurologic clinics.

[12]  J. Rich,et al.  Cancer stem cells in radiation resistance. , 2007, Cancer research.

[13]  I. Pollack,et al.  Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[15]  Hongye Liu,et al.  Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.

[16]  A. Merlo,et al.  Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells , 2007, Molecular Cancer Therapeutics.

[17]  R. Pallini,et al.  Telomerase inhibition impairs tumor growth in glioblastoma xenografts , 2006, Neurological research.

[18]  Ho-Yyoung Lee,et al.  Lonafarnib in cancer therapy , 2006, Expert opinion on investigational drugs.

[19]  Ning Lin,et al.  Noninvasive Bioluminescence Imaging of Luciferase Expressing Intracranial U87 Xenografts: Correlation with Magnetic Resonance Imaging Determined Tumor Volume and Longitudinal Use in Assessing Tumor Growth and Antiangiogenic Treatment Effect , 2006, Neurosurgery.

[20]  R. Arceci,et al.  Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. R. Bishop,et al.  The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling , 2005, Journal of Biological Chemistry.

[22]  R. Béliveau,et al.  Farnesyltransferase inhibitor SCH‐66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration , 2005, International journal of cancer.

[23]  J. Rhim,et al.  Farnesyltransferase inhibitor effects on prostate tumor micro‐environment and radiation survival , 2005, The Prostate.

[24]  Chitra Sarkar,et al.  Apoptosis and proliferation: correlation with p53 in astrocytic tumours , 2005, Journal of Neuro-Oncology.

[25]  G. Reifenberger,et al.  Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas , 2004, Acta Neuropathologica.

[26]  A. Ardizzoni,et al.  In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines. , 2004, Oncology reports.

[27]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[29]  T. Pawson,et al.  Manipulation of EphB2 Regulatory Motifs and SH2 Binding Sites Switches MAPK Signaling and Biological Activity* , 2003, The Journal of Biological Chemistry.

[30]  A. Chakravarti,et al.  The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. , 2002, Cancer research.

[31]  G. Yancopoulos,et al.  EphB ligand, ephrinB2, suppresses the VEGF‐ and angiopoietin‐1‐induced Ras/mitogen‐activated protein kinase pathway in venous endothelial cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Pawson,et al.  Downregulation of the Ras–Mitogen-Activated Protein Kinase Pathway by the EphB2 Receptor Tyrosine Kinase Is Required for Ephrin-Induced Neurite Retraction , 2001, Molecular and Cellular Biology.

[34]  J. Laterra,et al.  Signaling pathways in the induction of c‐met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma , 2001, Journal of neurochemistry.

[35]  R. Muschel,et al.  Ras regulation of radioresistance in cell culture. , 2001, Methods in enzymology.

[36]  W. R. Bishop,et al.  Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models. , 2001, Methods in enzymology.

[37]  S. Sebti,et al.  Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies , 2000, Oncogene.

[38]  W. Yung,et al.  Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. , 2000, Neuro-oncology.

[39]  A. Guha,et al.  Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects , 1999, Oncogene.

[40]  A Guha,et al.  Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.

[41]  I. Pollack,et al.  Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. , 1999, Neurosurgery.

[42]  R. Muschel,et al.  Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. , 1998, Cancer research.

[43]  W. Curran,et al.  Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.

[44]  T. Pawson,et al.  Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells , 1997, The EMBO journal.

[45]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[46]  David A. Cheresh,et al.  Regulation of Cell Motility by Mitogen-activated Protein Kinase , 1997, The Journal of cell biology.

[47]  N. Rosen,et al.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.

[48]  C. Der,et al.  Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.

[49]  D. Samid,et al.  Differences in radiation-induced micronuclei yields of human cells: influence of ras gene expression and protein localization. , 1993, International journal of radiation biology.

[50]  C. Ling,et al.  The role of the H-ras oncogene in radiation resistance and metastasis. , 1990, International journal of radiation oncology, biology, physics.

[51]  C. Ling,et al.  Radioresistance induced by oncogenic transformation. , 1989, Radiation research.